Sarclisa (isatuximab)

pCPA File Number: 23166

Negotiation Status:

Under consideration for negotiation

Indication(s):

In combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).

Sponsor/Manufacturer:

Sanofi Genzyme Canada

CDA-AMC Project Number:

PC0378-000

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable